Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21609443 | 0.90 | STAT3 (0.40) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL23244200 | 0.90 | STAT3 (0.43) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL12570393 | 0.87 | GAA (0.43) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL30091418 | 0.85 | STAT3 (0.37) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL12396684 | 0.85 | ALDH1A1 (0.49) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL31742337 | 0.85 | GAA (0.42) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL30644080 | 0.85 | GAA (0.45) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL23567067 | 0.84 | GAA (0.48) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL29380124 | 0.84 | G6PD (0.43) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL10163100 | 0.82 | GAA (0.46) | GAASTAT3ALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024198262-A1 | [18F] DEUTERATED FLUOROPROPYL TROPANE DERIVATIVE AND USE THEREOF | 江苏省原子医学研究所 | 2024-10-03 | — | — | WO | claimed |
| US-12617768-B2 | Radiolabeled cannabinoid receptor 2 ligand | HOFFMANN-LA ROCHE INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-3813888-B1 | RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| EP-3814337-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024198262-A1 | [18F] DEUTERATED FLUOROPROPYL TROPANE DERIVATIVE AND USE THEREOF | 江苏省原子医学研究所 | 2024-10-03 | — | — | WO | disclosed |
| US-20240308974-A1 | RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND | HOFFMANN LA ROCHE (US) | 2024-09-19 | — | — | US | disclosed |
| US-11999710-B2 | Radiolabeled cannabinoid receptor 2 ligand | HOFFMANN-LA ROCHE INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11655243-B2 | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2023-05-23 | — | — | US | disclosed |
| EP-3995155-A1 | RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND | F. Hoffmann-La Roche AG (CH) | 2022-05-11 | — | — | EP | disclosed |
| EP-3814337-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2021-05-05 | — | — | EP | disclosed |
| US-20210115012-A1 | RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND | HOFFMANN-LA ROCHE INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-20210115027-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-22 | — | — | US | disclosed |
| WO-2020002270-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115027-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS | CNR2, CNR1, TBXA2R | GAA 4745/4885STAT3 2812/4885ALDH1A1 1342/4885 |
| US-20240308974-A1 | RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND | CNR1, CNR2, GPR18 | GAA 4405/4885STAT3 4619/4885ALDH1A1 1913/4885 |
| US-20210115012-A1 | RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND | CNR1, CNR2, GPR18 | GAA 4405/4885STAT3 4619/4885ALDH1A1 1913/4885 |
| US-12617768-B2 | Radiolabeled cannabinoid receptor 2 ligand | CNR1, CNR2, GPR3 | GAA 4771/4885STAT3 2879/4885ALDH1A1 4013/4885 |
| US-11655243-B2 | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists | CNR2, CNR1, TBXA2R | GAA 4745/4885STAT3 2812/4885ALDH1A1 1342/4885 |
| US-11999710-B2 | Radiolabeled cannabinoid receptor 2 ligand | CNR1, CNR2, GPR18 | GAA 4405/4885STAT3 4619/4885ALDH1A1 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.